Baird lowered the firm’s price target on Praxis Precision (PRAX) to $73 from $117 and keeps an Outperform rating on the shares. The firm updated its model following its Q4 report where Ulixacaltamide is no longer essential for upside.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRAX:
- Praxis Precision Medicines: A Compelling Buy Amidst Promising Pipeline Developments
- Praxis Precision price target lowered to $105 from $120 at H.C. Wainwright
- Praxis Precision price target lowered to $65 from $111 at Deutsche Bank
- Positive Outlook on Praxis Precision Medicines Amidst Phase 3 ET Program Challenges
- Praxis Precision price target lowered to $61 from $114 at TD Cowen